BioCentury | Aug 13, 2007
Product Development

Faster followers in pain

...YM: Personalized dosing In 2005, YM Biosciences Inc. paid $3.7 million in stock to purchase Delex Therapeutics Inc....
BioCentury | May 9, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...are eligible for additional YM shares if certain milestones are met (see BioCentury, April 18). Delex Therapeutics Inc....
BioCentury | Apr 18, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...YM will pay Delex shareholders an additional C$4.8 million (US$3.9 million) in cash or stock. Delex Therapeutics Inc....
BioCentury | Oct 11, 2004
Clinical News

AeroLEF: Phase IIa data

...Phase IIa trial in 24 patients, 95% of patients safely self-titrated AeroLEF and achieved analgesia. Delex Therapeutics Inc....
BioCentury | Jun 14, 2004
Clinical News

AeroLEF: Phase IIa complete

...trial in 24 patients. The company said data are expected over the next few months. Delex Therapeutics Inc....
BioCentury | Mar 8, 2004
Clinical News

AeroLEF fentanyl: Phase II

...Delex began dosing in a Canadian Phase II trial of AeroLEF in 24 patients. Delex Therapeutics Inc....
BioCentury | Nov 3, 2003
Company News

Delex Therapeutics board of directors update

Delex Therapeutics Inc. , Mississauga, Ontario Business: Drug delivery Appointed: David Howard, chairman of Angiotech Pharmaceuticals Inc. WIR Staff...
Items per page:
1 - 7 of 7
BioCentury | Aug 13, 2007
Product Development

Faster followers in pain

...YM: Personalized dosing In 2005, YM Biosciences Inc. paid $3.7 million in stock to purchase Delex Therapeutics Inc....
BioCentury | May 9, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...are eligible for additional YM shares if certain milestones are met (see BioCentury, April 18). Delex Therapeutics Inc....
BioCentury | Apr 18, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...YM will pay Delex shareholders an additional C$4.8 million (US$3.9 million) in cash or stock. Delex Therapeutics Inc....
BioCentury | Oct 11, 2004
Clinical News

AeroLEF: Phase IIa data

...Phase IIa trial in 24 patients, 95% of patients safely self-titrated AeroLEF and achieved analgesia. Delex Therapeutics Inc....
BioCentury | Jun 14, 2004
Clinical News

AeroLEF: Phase IIa complete

...trial in 24 patients. The company said data are expected over the next few months. Delex Therapeutics Inc....
BioCentury | Mar 8, 2004
Clinical News

AeroLEF fentanyl: Phase II

...Delex began dosing in a Canadian Phase II trial of AeroLEF in 24 patients. Delex Therapeutics Inc....
BioCentury | Nov 3, 2003
Company News

Delex Therapeutics board of directors update

Delex Therapeutics Inc. , Mississauga, Ontario Business: Drug delivery Appointed: David Howard, chairman of Angiotech Pharmaceuticals Inc. WIR Staff...
Items per page:
1 - 7 of 7